ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Context Mosun, a full-length, humanized, IgG1 CD20×CD3 bispecific antibody, demonstrated efficacy/safety in relapsed/refractory DLBCL (NCT02500407; Schuster, et al. ASH 2019). The phase I/II multicenter GO40554 (NCT03677154) study showed similar results for elderly/unfit patients with first-line DLBCL intolerant of full-dose chemoimmunotherapy (CIT) (Olszewski, et al. ASH 2020). Objective To describe updated GO40554 study data. Methods Two safety-evaluation cohorts were assessed (Mosun 13.5 mg and 30 mg), then a 30 mg expansion phase. Patients were aged ≥80 years; 60–79 years with impairment in ≥1 activity of daily living (ADL); instrumental ADL; or impaired cardiac, renal, or liver functio…

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

© 2018 The Authors.

MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES